Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: Association with carcinomas with serous differentiation

被引:22
作者
Garcia, A [1 ]
Bussaglia, E [1 ]
Machin, P [1 ]
Matias-Guiu, X [1 ]
Prat, J [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Cruz & San Pablo, Dept Pathol, E-08025 Barcelona, Spain
关键词
ovarian tumors; loss of heterozygosity; 17q; BRCA-1; serous carcinoma; mixed endometrioid-serous carcinomas; sporadic ovarian cancers;
D O I
10.1097/00004347-200004000-00009
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Loss of heterozygosity (LOH) on chromosome 17q is frequent in epithelial ovarian tumors, but its clinicopathologic significance remains to be elucidated. DNA of 50 patients with epithelial ovarian tumors was extracted from blood and fram fresh-frozen and paraffin-embedded tissue (14 benign, 7 borderline, and 29 malignant). Six microsatellite loci were amplified by PCR (D17S250, TRHA1, D17S800, D17S855, D17S579, D17S513). LOH was scored by the absence or reduction of the signal to less than 50% of one of the alleles in tumor DNA compared with normal DNA. LON: was identified on chromosome 17q in at least one locus in 12 tumors (24%), all of them carcinomas (12 of 29 tumors, 41.3%). It occurred more frequently among high-grade serous carcinomas (8 of 14 tumors, 57%) and mixed endometrioid-serous carcinomas (2 of 5, 40%). LOH was detected in all informative markers of 10 tumors, suggesting the complete loss of an entire chromosome 17 homologue. Patients with LOH-positive carcinomas were older than those with LOH-negative malignant tumors (mean ages 67 and 49). The results support the hypothesis that LOH on chromosome 17q may be associated with the development of ovarian cancers in elderly patients, particularly with high-grade serous or mixed endometrioid-serous carcinomas.
引用
收藏
页码:152 / 157
页数:6
相关论文
共 38 条
[11]  
JACOBS IJ, 1993, CANCER RES, V53, P1218
[12]   Tumour biological features of BRCA1-induced breast and ovarian cancer [J].
Johannsson, OT ;
Idvall, I ;
Anderson, C ;
Borg, A ;
Barkardottir, RB ;
Egilsson, V ;
Olsson, H .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (03) :362-371
[13]  
Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO
[14]  
2-Y
[15]  
LEE JH, 1990, CANCER RES, V50, P2724
[16]   CPG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site [J].
Mancini, DN ;
Rodenhiser, DI ;
Ainsworth, PJ ;
O'Malley, FP ;
Singh, SM ;
Xing, WR ;
Archer, TK .
ONCOGENE, 1998, 16 (09) :1161-1169
[17]  
Marcus JN, 1997, CANCER-AM CANCER SOC, V80, P543, DOI 10.1002/(SICI)1097-0142(19970801)80:3+<543::AID-CNCR4>3.0.CO
[18]  
2-A
[19]  
Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO
[20]  
2-W